Marat Fudim1,2, Sabina Sayeed1, Haolin Xu3, Roland A Matsouaka3, Paul A Heidenreich4, Eric J Velazquez5, Clyde W Yancy6, Gregg C Fonarow7, Adrian F Hernandez1,2, Adam D DeVore1,2. 1. Duke Clinical Research Institute, Durham, NC (M.F., S.S., A.F.H., A.D.D.). 2. Division of Cardiology, Duke University Medical Center, Durham, NC (M.F., A.F.H., A.D.D.). 3. Department of Biostatistics and Bioinformatics, Duke University, Durham, NC (H.X., R.A.M.). 4. Section of Cardiology, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA (P.A.H.). 5. Division of Cardiology, Yale University, New Haven, CT (E.J.V.). 6. Division of Cardiology, Northwestern University, Chicago, IL (C.W.Y.). 7. Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles Medical Center (G.C.F.).
Abstract
BACKGROUND: In PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-pro BNP in Patients Stabilized From an Acute Heart Failure Episode), the in-hospital initiation of sacubitril/valsartan in patients hospitalized for acute decompensated heart failure (ADHF) was well-tolerated and led to improved outcomes. We aim to determine the representativeness of the PIONEER-HF trial among patients hospitalized for ADHF using real-world data. METHODS: The study population was derived from all patients discharged alive for ADHF in the Get With The Guidelines-HF registry from 2006 to 2018 with HF with reduced ejection fraction (HFrEF; all HFrEF with ADHF). We then determined the proportion of patients meeting PIONEER-HF eligibility criteria (PIONEER-HF eligible) and those meeting a set of limited eligibility criteria (actionable cohort). Rates of HF readmissions and all-cause mortality were then compared between the all HFrEF with ADHF, PIONEER-HF eligible, and actionable cohorts using linked Medicare claims data. RESULTS: A total of 99 767 patients with HFrEF in Get With The Guidelines-HF were hospitalized for ADHF. PIONEER-HF inclusion criteria were met by 71 633 (71.8%) patients, and both inclusion and exclusion criteria were met by 20 704 (20.8%) patients. Further, 68 739 (68.9%) patients met the criteria for the actionable cohort. Among the Centers for Medicare and Medicaid-linked patients, the HF rehospitalization rate at 1 year was 35.1% (95% CI, 34.5-35.8) for all HFrEF with ADHF patients, 32.6% (95% CI, 31.3-33.9) for the PIONEER-HF eligible cohort, and 33.1% (95% CI, 32.3-33.9) for the actionable cohort. The 1-year all-cause mortality was 36.7% (95% CI, 36.1-7.4) for all HFrEF with ADHF patients, 31.6% (95% CI, 30.3-32.9) for the PIONEER-HF eligible cohort, and 32.2% (95% CI, 31.4-33.0) for the actionable cohort. CONCLUSIONS: Patient characteristics and clinical outcomes for patients eligible for PIONEER-HF only modestly differ when compared with those encountered in routine practice, suggesting that the in-hospital initiation of sacubitril/valsartan should be routinely considered for patients with HFrEF hospitalized for ADHF.
BACKGROUND: In PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-pro BNP in Patients Stabilized From an Acute Heart Failure Episode), the in-hospital initiation of sacubitril/valsartan in patients hospitalized for acute decompensated heart failure (ADHF) was well-tolerated and led to improved outcomes. We aim to determine the representativeness of the PIONEER-HF trial among patients hospitalized for ADHF using real-world data. METHODS: The study population was derived from all patients discharged alive for ADHF in the Get With The Guidelines-HF registry from 2006 to 2018 with HF with reduced ejection fraction (HFrEF; all HFrEF with ADHF). We then determined the proportion of patients meeting PIONEER-HF eligibility criteria (PIONEER-HF eligible) and those meeting a set of limited eligibility criteria (actionable cohort). Rates of HF readmissions and all-cause mortality were then compared between the all HFrEF with ADHF, PIONEER-HF eligible, and actionable cohorts using linked Medicare claims data. RESULTS: A total of 99 767 patients with HFrEF in Get With The Guidelines-HF were hospitalized for ADHF. PIONEER-HF inclusion criteria were met by 71 633 (71.8%) patients, and both inclusion and exclusion criteria were met by 20 704 (20.8%) patients. Further, 68 739 (68.9%) patients met the criteria for the actionable cohort. Among the Centers for Medicare and Medicaid-linked patients, the HF rehospitalization rate at 1 year was 35.1% (95% CI, 34.5-35.8) for all HFrEF with ADHF patients, 32.6% (95% CI, 31.3-33.9) for the PIONEER-HF eligible cohort, and 33.1% (95% CI, 32.3-33.9) for the actionable cohort. The 1-year all-cause mortality was 36.7% (95% CI, 36.1-7.4) for all HFrEF with ADHF patients, 31.6% (95% CI, 30.3-32.9) for the PIONEER-HF eligible cohort, and 32.2% (95% CI, 31.4-33.0) for the actionable cohort. CONCLUSIONS: Patient characteristics and clinical outcomes for patients eligible for PIONEER-HF only modestly differ when compared with those encountered in routine practice, suggesting that the in-hospital initiation of sacubitril/valsartan should be routinely considered for patients with HFrEF hospitalized for ADHF.
Authors: Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani Journal: Circulation Date: 2019-03-05 Impact factor: 29.690
Authors: Petar M Seferovic; Piotr Ponikowski; Stefan D Anker; Johann Bauersachs; Ovidiu Chioncel; John G F Cleland; Rudolf A de Boer; Heinz Drexel; Tuvia Ben Gal; Loreena Hill; Tiny Jaarsma; Ewa A Jankowska; Markus S Anker; Mitja Lainscak; Basil S Lewis; Theresa McDonagh; Marco Metra; Davor Milicic; Wilfried Mullens; Massimo F Piepoli; Giuseppe Rosano; Frank Ruschitzka; Maurizio Volterrani; Adriaan A Voors; Gerasimos Filippatos; Andrew J S Coats Journal: Eur J Heart Fail Date: 2019-08-30 Impact factor: 15.534
Authors: Kishan S Parikh; Steven J Lippmann; Melissa Greiner; Paul A Heidenreich; Clyde W Yancy; Gregg C Fonarow; Adrian F Hernandez Journal: Circulation Date: 2017-05-23 Impact factor: 29.690
Authors: Eric J Velazquez; David A Morrow; Adam D DeVore; Carol I Duffy; Andrew P Ambrosy; Kevin McCague; Ricardo Rocha; Eugene Braunwald Journal: N Engl J Med Date: 2018-11-11 Impact factor: 91.245
Authors: Steven M Hollenberg; Lynne Warner Stevenson; Tariq Ahmad; Vaibhav J Amin; Biykem Bozkurt; Javed Butler; Leslie L Davis; Mark H Drazner; James N Kirkpatrick; Pamela N Peterson; Brent N Reed; Christopher L Roy; Alan B Storrow Journal: J Am Coll Cardiol Date: 2019-09-13 Impact factor: 24.094
Authors: Stephen J Greene; Gregg C Fonarow; Adam D DeVore; Puza P Sharma; Muthiah Vaduganathan; Nancy M Albert; Carol I Duffy; C Larry Hill; Kevin McCague; J Herbert Patterson; John A Spertus; Laine Thomas; Fredonia B Williams; Adrian F Hernandez; Javed Butler Journal: J Am Coll Cardiol Date: 2019-03-04 Impact factor: 24.094
Authors: David A Morrow; Eric J Velazquez; Adam D DeVore; Margaret F Prescott; Carol I Duffy; Yared Gurmu; Kevin McCague; Ricardo Rocha; Eugene Braunwald Journal: Eur Heart J Date: 2019-10-21 Impact factor: 29.983
Authors: Muthiah Vaduganathan; Stephen J Greene; Shuaiqi Zhang; Maria Grau-Sepulveda; Adam D DeVore; Javed Butler; Paul A Heidenreich; Joanna C Huang; Michelle M Kittleson; Karen E Joynt Maddox; James J McDermott; Anjali Tiku Owens; Pamela N Peterson; Scott D Solomon; Orly Vardeny; Clyde W Yancy; Gregg C Fonarow Journal: JAMA Cardiol Date: 2020-11-13 Impact factor: 14.676
Authors: Matthew T Mefford; Sandra Y Koyama; Justine De Jesus; Rong Wei; Heidi Fischer; Teresa N Harrison; Pauline Woo; Kristi Reynolds Journal: J Am Heart Assoc Date: 2022-03-24 Impact factor: 6.106